Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. Issue 9 (23rd July 2013)

• Record Type: Journal Article
• Authors: Pavlik, Tomas; Janousova, Eva; Mayer, Jiri; Indrak, Karel; Jarosova, Marie; Klamova, Hana; Zackova, Daniela; Voglova, Jaroslava; Faber, Edgar; Karas, Michal; Machova Polakova, Katerina; Racil, Zdenek; Demeckova, Eva; Demitrovicova, Ludmila; Tothova, Elena; Chudej, Juraj; Markuljak, Imrich; Cmunt, Eduard; Kozak, Tomas; Muzik, Jan; Dusek, Ladislav
• Is Part Of: American journal of hematology. Volume 88:Issue 9(2013:Sep.)
• Page Start: 790
• Page End: 797
• Publication Date: 2013-07-23
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23508
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of <italic>BCR‐ABL1</italic> and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so‐called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia‐free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the <italic>BCR‐ABL1</italic> transcripts at 3 months. The 5‐year CCI was 94.3% in patients with <italic>BCR‐ABL1</italic> transcripts ≤ 10% and 57.1% in patients with <italic>BCR‐ABL1</italic> transcripts > 10% (<italic>P</italic> = 0.005). Therefore, the examination of <italic>BCR‐ABL1</italic> transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks. Am. J. Hematol. 88:790–797, 2013. © 2013 Wiley Periodicals, Inc.</p> </abstract>